Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Therapeutic Potential BPC-157 is modified for greater stability than its parent compound and is shown to have systemic effects without the need for a carrier agent
Peripheral effects Via the AMY2 and AMY3 receptors Cagrilintide acts peripherally: Slowing of gastric emptying , stronger than with GLP-1 Suppression of postprandial glucagon , helps control postprandial glycemic spikes Modulation of bone remodeling (via AMY3), a neutral effect, but clinically monitored Synergy with GLP-1 (the mechanistic basis of CagriSema) The main innovation is the complementarity with the GLP-1 pathway : GLP-1 suppresses appetite via the arcuate nucleus of the hypothalamus (POMC neurons, AgRP/NPY inhibition) Amylin suppresses appetite via the area postrema (CGRP-like neurons) Two independent centers, two independent mechanisms
Administration Precautions: Bacteriostatic Water for Injection should never be injected intravenously (or intra-spinally) by itself without first being mixed with a medication or appropriate solute
Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing Current Pharmaceutical Design, 2018, Volume 24 (Issue 18), Pages 1972-1989
